MRTX News and Press, Mirati Therapeutics Inc. From 11/24/23

2023-11-24 06:48:01 ET More on Innovent Biologics Historical earnings data for Innovent Biologics Financial information for Innovent Biologics Historical earnings data for Innovent Biologics, Inc. Financial information for Innovent Biologics, Inc. For...

NEW YORK, NY / ACCESSWIRE / November 15, 2023 / Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: PCTEL, Inc. (NASDAQ:PCTI)'s sal...

2023-11-12 01:40:08 ET Summary An application for Accelerated Approval of avutometinib + defactinib for low-grade serous ovarian cancer patients is expected in the first half of 2024. The ongoing RAMP-301 study is being done to keep avutometinib + defactinib for LGSC on the market...

2023-11-10 07:53:09 ET More on Mirati Therapeutics Mirati Therapeutics: Anatomy Of A Long Simmering Buyout Bristol-Myers' Mirati Takeover: Pharma Is Either Buying Crown Jewels Or A Dud Mirati: Expansion Of Adagrasib With sNDA And Combination Studies Bristol-M...

Mirati Therapeutics Receives Positive Opinion from CHMP for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation Following a Re-Examination Procedure PR Newswire SAN DIEGO, Calif. and ZUG,...

Mirati Therapeutics Inc. (MRTX) is expected to report $-2.92 for Q3 2023

2023-11-06 11:48:57 ET More on Mirati Therapeutics Mirati Therapeutics: Anatomy Of A Long Simmering Buyout Bristol-Myers' Mirati Takeover: Pharma Is Either Buying Crown Jewels Or A Dud Mirati: Expansion Of Adagrasib With sNDA And Combination Studies Bristol-M...

Mirati Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate Updates PR Newswire SAN DIEGO , Nov. 6, 2023 /PRNewswire/ -- Mirati Therapeutics, Inc. ® (NASDAQ: MRTX), a commercial stage biotechnology company, today announced f...

Mirati Therapeutics Receives Approval from the MHRA for KRAZATI (adagrasib) as a Targeted Treatment Option for Patients with Advanced Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation PR Newswire SAN DIEGO and ZUG, Switzerland , Nov. 3, 2023 /P...

SAN DIEGO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Kura Oncology, Inc. (NASDAQ: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, and Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial-stage targeted oncology com...